Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Encoded Therapeutics raises $275 million in Series F financing to advance ETX101 through pivotal development and accelerate its precision genetic medicines neurology pipeline.
PRIVATESep 09, 2026•about 2 hours ago
Amount Raised
$275 Million
Round Type
Series F
OrlandoBiotechnologyHealth CareTherapeutics
Description
Encoded Therapeutics has successfully raised $275 million in its Series F financing round. The funds will be utilized to advance its lead product, ETX101, and accelerate the development of its precision genetic medicines for neurology. This financing is a significant step forward in the company's mission to deliver innovative treatments. The investment showcases strong confidence in the company's pipeline and growth potential.
Company Information
Company
Encoded Therapeutics
Location
Orlando, Florida, United States
About
Encoded Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders. They specialize in creating potentially disease-modifying therapies that aim to improve the lives of individuals affected by these challenging conditions. The company's proprietary vector engineering approach integrates novel regulatory elements and payloads with AAV vectors. Their flagship clinical program, ETX101, targets the underlying causes of Dravet syndrome.
Don't miss Encoded Therapeutics's next move
Get an email the moment Encoded Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
3 contacts
Predictive Intelligence
Strategic
ML-powered predictions for Encoded Therapeutics's next move
OrlandoBiotechnologyHealth CareTherapeutics